Med. praxi. 2010;7(11):415-418

Progress in therapy of irritable bowel syndrome

prof.MUDr.Jiří Ehrmann, CSc.
II. interní klinika LF UP a FN Olomouc

Irritable bowel syndrome (IBS) is the most common functional gut disorders and is charakterized by abdomen pain with altered stool

frequency or consistency. Symptoms are induced by physiological aberrations (like dysmotility and visceral hypersensitivity) or by the

mechanisms of the initial inflammation (infection ?) and neuro-immune interaction. This is also the top of the contemporary research.

On the other hand the therapy of the day remain on the level of the decrease of main symptoms; abdominal pain, constipation, diarhoea

and psychological factors. Sulpride, antagonist of the D1 and D 3 receptors in dose 3time/d 50 or 100 mg is the first step of the pharmaceutical

treatment of IBS due to anxiolytic and analgetic effects.

Keywords: irritable bowel syndrome, treatment, sulpride

Published: January 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ehrmann J. Progress in therapy of irritable bowel syndrome. Med. praxi. 2010;7(11):415-418.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Douglas A, Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1337-1390. Go to original source...
    2. Thomayer J. Pablánový zánět střevní. Enteritis pseudomembranacea. Colica mucosa seu membranacea. In: Thomayer J. Patghologie a therapie nemocí vnitřních. Praha: Bursík & Kohout, 1921: 831-832.
    3. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122: 1500-1511. Go to original source... Go to PubMed...
    4. Inadomi JM, Fennerty MB, Björkman D. Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 671-682. Go to original source... Go to PubMed...
    5. Akbar A, Walters JRF, Ghosh S. Visceral hypersensitivity in irritable bowel syndrome: molecular mechanisms and therapeutic agents. Aliment Pharmacol Ther 2009; 30: 423-435. Go to original source... Go to PubMed...
    6. Ritchie J. Pain from distension of the pelvis colon by inflating a balloon in the irritable colon syndrome. Gut 1973; 14: 125-132. Go to original source... Go to PubMed...
    7. Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001; 48: 14-19. Go to original source... Go to PubMed...
    8. Herschbach P, et al. Psychological factors in functional gastrointestinal disorders: characteristic of the disorder or of the illness behaviour? Psychosom Med 1999; 61: 148-153. Go to original source... Go to PubMed...
    9. Chaudhary NA, Truelove SC. The irritable colon syndrome. A study of the clinical features, predisponsing causes and prognosis in 130 cases. Q J Med 1962; 31: 307-322.
    10. Barbara G, De Giorgio R, et al. Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice. Gastroenterology 2001; 120: 1729-1736. Go to original source... Go to PubMed...
    11. Isgar B, et al. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983; 24: 190-192. Go to original source... Go to PubMed...
    12. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel. syndrome. Am J Gastroenterology 2003; 98; 1578-1583. Go to original source... Go to PubMed...
    13. Ehrmann J. Současné možnosti terapie dráždivého tračníku. Klin Farmakol Farm 2008; 22: 99-102.
    14. Ehrmann J. Dráždivý tračník a jeho léčba. Causa sub 2009; 12: 126-129.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.